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the triple positivity was significantly associated with male gender (OR=3.5; p=0.02), the presence of rheumatoid nodules (OR=5,3; p=0.015) and pulmonary involvement (OR=2.6; p=0.007). Anti-IFI16 auto-Abs were associated to male gender independently of the presence of the other two auto-Abs. Conclusions: Our study demonstrated that anti-CEP-1 auto-Abs may participate to the development of RA-associated pulmonary manifestation together with anti-CCP and that the assessment of multiple auto-Abs in daily practice may help clinician to stratify RA patients at identify those at higher risk to develop extra-articular manifestations. Background: Monitoring of patients with rheumatoid arthritis (RA) requires assessment of biomarkers reflecting disease activity and its progression. There is a need for non-invasive markers for frequent monitoring of disease severity and progression as well as response to therapy. Objectives: Serological markers together with clinical parameters was tested in a multi-marker model to assess its ability to objectively predict progression of RA. Methods: Current post-hoc analysis included RA patients from the biomarker substudy of the phase III clinical study LITHE investigating the safety and efficacy of tocilizumab [1] [2] [3] [4] . Patients had moderate/severe, active RA. In addition, only patients of the placebo arm and with total sharp score (SHP) recorded at baseline (BL), week 24 (W24) and W52 were included. Progressors were defined as the delta from BL to W24 and W24 to W52. Biochemical markers reflecting tissue turnover (table) were assessed at BL and W16. Associations with structural progression (deltaSHP) were investigated by spearman's r, least squared multivariate and logistic regression. Covariates were CRP, sex, BMI, age, disease duration, DAS-ESR, no. prior DMARDs/aTNF use and SHP/BL. The data were divided into a training and confirmation set; 1) association between markers/W16 and deltaSHP/W52 (n=31 prog./42 non-prog.), 2) association between markers/BL and deltaSHP/W24 (n=33/48). 
Conclusions:
We demonstrated that a multi-marker model was able to pint-point, which patients were more likely to be structural progressors. Such first steps to build a progression model, rather than a score reflecting disease activity only, may enrich clinical studies with structurally active diseaese. Importantly, the markers with strongest influence were those associated with MMP-driven bone (ICTP) and connective tissue (C1M) remodelling. Background: Medication adherence is very important in the treatment of rheumatoid arthritis (RA). However, medication adherence of the patients with RA was not optimal in many of the studies (1-2). Objectives: The purpose of this study was to investigate the medication adherence in tightly controlled RA patients and reasons of non-adherence. Methods: A total of 82 RA patients (65 women and 17 men) who followed regularly in our outpatient clinic were included. Socio-demographic features and medical history were collected. The eight-item Morisky scale (MMAS-8) was used to evaluate adherence to medication. Disease activity score (DAS28), health assessment questionnaire (HAQ), mini mental state examination (MMSE) test and Beck depression inventory (BDI) were evaluated. Results: According to Morisky scale, 34.1%, 15.9% and 50% of our patients were categorized as low, moderate and high adherence, respectively. The most prevalent noticed barriers for adherence were forgetting medication, inadequate information about using instructions, side effects of medications (Table 1) . Socio demographic features, duration of disease, type and number of drugs used per day, the route of drug administration, co-morbid diseases, body mass index, smoking and alcohol consumption were not found to be associated with medication adherence, whereas low MMSE and high BDI score were associated with low medication adherence (p=0.009 and p=0.011, respectively). We found that the disease activity was significantly higher in non-adherent cases (p=0.00) ( Table 2 ). Conclusions: Our RA patients who were closely followed had 50% high medication adherence. This rate is quite high compared to other studies using MMAS-8. It should be kept in mind that tight control and adequate communication increase medication adherence but different parameters may also be effective. Assessing cognitive disorders and emotional problems of the patient will be beneficial for improving adherence and controlling disease activity.
